1. Liquiritin ameliorates metabolic and endocrine alterations in a mouse model of polycystic ovary syndrome
- Author
-
Zhi Li, Yan Liu, Hai-Ou Liu, Zhi-Yong Wu, Cong-Jian Xu, Fei-Fei Zhang, and Yong-Qing Zhu
- Subjects
Immunologic diseases. Allergy ,RC581-607 ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract. Objective:. Altered bile acid transformation induces low-grade chronic inflammation and may play an important role in the pathophysiology of polycystic ovary syndrome (PCOS). Liquiritincan regulate bile acid metabolism and anti-inflammatory properties; however, limited information is available regarding its therapeutic potential in PCOS. Methods:. Female C57BL/6 mice were randomly assigned into four groups (n = 6 mice/group): the control, letrozole or dehydroepiandrosterone-induced PCOS groups, PCOS + 20 mg/kg liquiritin group, and control + liquiritin groups. After 21 days of treatment, the mice were euthanized, and the associated metabolism indications were investigated. Ovarian histological examinations were performed, and serum hormone concentration was measured. The expression of key genes involved in steroid hormone synthesis, ovarian follicle development, and ovulation was assessed. Results:. Liquiritin reduced fasting blood glucose levels and increased insulin sensitivity compared to the PCOS group. Liquiritin also significantly decreased serum levels of total testosterone (P
- Published
- 2022
- Full Text
- View/download PDF